EVALUATION OF ANTIDYSLIPIDEMIC EFFECT OF MANGIFERIN AND AMAROGENTIN FROM SWERTIA CHIRAYITA EXTRACT IN HFD INDUCED CHARLES FOSTER RAT MODEL AND THEIR DOCKING STUDIES

Abstract

In continuation of our research programs on bio evaluation of medicinal plants in India, we have investigated antidyslipidemic and antioxidant potential of Swertia chirayita (SC) plant, a potent antidiabetic and its isolated marker. The standardized hot water extracts of different batches from whole plant of Swertia chirayita, were tested in vivo for their antidyslipidemic activity in High fat diet (HFD) induced dyslipidemic Charles Foster rats. Further solvent fractionation and isolation resulted in identification of antidyslipidemic Mangiferin (MG) and Amarogentin (AM). Treatment of hyperlipidemic rats with MG and AM caused reduction in plasma levels of Low density lipoprotein (LDL) 24, 26% and very low - density lipoprotein (VLDL) 19, 25% as well as increase in levels of High density lipoprotein (HDL) 18, 22% respectively, at 200mg/kg doses. In rats with HFD, MG and AM significantly reduced levels of VLDL lipids (26% and 27%) as well as Low density lipoprotein-Total cholesterol (LDL-TC) 27% and 30% in hyperlipidemic rats at 100 and 200 mg/kg doses. This is first report of AM demonstrated as antidyslipidemic agent. In addition, both MG and AM also demonstrated more effective inhibition at 5μM and 10 μM of HMGR (HMG-CoA reductase) in comparison to Pravastatin, which was further confirmed by docking studies.